Contact

Our portfolio

Parkinnova Therapeutics

Parkinnova Therapeutics, focuses on developing novel treatments for midbrain dopamine disorders like Parkinson’s disease. The company targets the PDE11a pathway to upregulate dopamine production. Parkinnova aims to bring innovative therapies to clinical trials, addressing significant unmet needs in neurodegenerative diseases. The company is committed to advancing neuroscience through cutting-edge research.

  • Institute: University of Amsterdam
Industry: Neuroscience, Therapeutics
  • Founding year: 2024
Visit website

Want to get in contact about Parkinnova Therapeutics?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

longform.ai
Using AI to restructure audio data, such as podcasts and webinars.
Arthrogen
Developing local gene therapy for chronic diseases, Arthrogen utilizes viral-mediated gene transfer to treat conditions like rheumatoid arthritis.
Haermonics
Preventing post-surgical complications with the PURE pericardial flushing device.
Confocal NL
Enhancing microscopes with low-power super-resolution imaging solutions.
longform.ai
Using AI to restructure audio data, such as podcasts and webinars.
Arthrogen
Developing local gene therapy for chronic diseases, Arthrogen utilizes viral-mediated gene transfer to treat conditions like rheumatoid arthritis.
Haermonics
Preventing post-surgical complications with the PURE pericardial flushing device.
Confocal NL
Enhancing microscopes with low-power super-resolution imaging solutions.
Explore full AAV portfolio
Contact